The international REQUITE cohort included 1,758 men diagnosed with non-metastatic prostate cancer who received radiotherapy between 2014 and 2016 and completed the EORTC QLQ-C30 at baseline and repeatedly up to five years. Investigators collected prospectively reported outcomes intended to capture cancer-related fatigue and related quality-of-life domains. The abstract did not provide specific radiotherapy dose schedules, fractionation details, or ADT timing in the source text; those methodological specifics were not reported in the supplied material.
Across the full observation period, 608 of 1,758 men—about 35%—experienced clinically important fatigue (defined in the study as a score ≥39/100 on the EORTC QLQ-C30) at least once. Two years after radiotherapy, point prevalence of clinically important fatigue was 14%. Logistic regression models, as reported by the authors, associated fatigue at two years with several baseline characteristics: a higher pre-radiotherapy fatigue score (odds ratio [OR] 8.67), self-reported diabetes (OR 1.94), higher body mass index (OR 1.07 per unit), and older age (OR 1.03 per year). The study team observed that elevated baseline fatigue conferred the strongest relative risk for later fatigue.
Long-term fatigue did not occur in isolation. Data indicated strong links between persistent fatigue and other patient-reported problems: pain, insomnia, pelvic symptoms, reduced functional status across domains, and lower overall quality of life. The cohort showed co-occurrence of these symptom clusters, suggesting multimodal contributors to sustained fatigue after radiotherapy. The supplied abstract text did not elaborate on causal mechanisms, biochemical markers, or interventional responses; those elements were outside the reported summary.
The authors applied latent class growth analysis to model longitudinal fatigue trajectories and identified four discrete patterns among patients. Nearly half the cohort—45%—followed a low-fatigue trajectory. A similar proportion—42%—followed a moderate trajectory with stable, intermediate fatigue levels. Two smaller groups had divergent long-term patterns: an elevated-but-decreasing trajectory (8%) and an increasing fatigue trajectory (6%). The study team presented these classes as evidence that fatigue courses vary substantially between patients over five years of follow-up.
Multinomial regression linked baseline diabetes to movement between trajectory classes. Specifically, the presence of diabetes was associated with a six percentage point higher probability of belonging to the increasing fatigue trajectory compared with patients without diabetes. The abstract did not report additional effect sizes for other comorbidities or the full set of covariates included in the multinomial models; such methodological detail was not provided in the supplied text. Nonetheless, diabetes emerged as a measurable modifier of long-term symptom course in this cohort.
Investigators concluded that early identification of men at risk for long-term fatigue could inform follow-up strategies. The data indicated that patients with higher pre-radiotherapy fatigue scores and those with diabetes may require closer monitoring within risk-stratified aftercare programmes. The authors noted the strong association between persistent fatigue and co-occurring symptoms—pain, insomnia, pelvic dysfunction, functional impairment, and worse quality of life—supporting a comprehensive symptom assessment approach rather than an isolated focus on fatigue alone.
Limitations and unanswered questions documented in the abstract
The abstract did not include granular radiotherapy treatment parameters, details on androgen deprivation therapy exposure, or deeper mechanistic data linking biological pathways to reported fatigue trajectories; those specifics were not reported in the provided source text. The study report therefore leaves open several practical questions documented by the authors: which interventions can alter trajectory membership, how radiotherapy technique or ADT exposure modifies long-term fatigue risk, and which measurable biomarkers—if any—predict deterioration versus recovery. The supplied summary emphasizes the need for targeted monitoring of high-risk patients, particularly those with elevated baseline fatigue and diabetes, but does not report tested strategies to reduce long-term fatigue.
Practical takeaways for clinicians
The REQUITE data set provides a longitudinal, patient-reported view of post-radiotherapy fatigue in non-metastatic prostate cancer. The authors recommended early identification and monitoring of susceptible patients; the abstract did not present tested interventions or definitive mechanistic explanations, leaving those as clear next clinical and research questions to be addressed in subsequent reports from the study team.